Progression-free survival (PFS) under molecular therapy compared to progression-free survival under the prior treatment regimen was not statistically different but showed a trend in favor of the targeted therapy (Fig. 7 a).
← all excerpts
Molecular diagnostics and therapies for gastrointestinal tumors: a real-world experience.
1
—
—